Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / SNY - Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis | Benzinga

SNY - Merck Germany's Two Pivotal Trials Flunk In Multiple Sclerosis | Benzinga

Sanofi

Merck KGaA (OTC: MKGAF) (OTC: MKKGY) says its two Phase 3 EVOLUTION trials (evolutionRMS 1 and evolutionRMS 2) of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to Sanofi SA's (NASDAQ: SNY) Aubagio (teriflunomide).

The data showed ...

Full story available on Benzinga.com
Stock Information
Company Name: Sanofi
Stock Symbol: SNY
Market: NASDAQ
Website: sanofi.com
Menu
SNY SNY Quote SNY Short SNY News SNY Articles SNY Message Board
Get SNY Alerts

News, Short Squeeze, Breakout and More Instantly...